Patents by Inventor James Robert Henry

James Robert Henry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10490952
    Abstract: A connector assembly includes a cage member having a plurality of walls defining a module cavity for a pluggable module. The walls include a top wall, a bottom wall and side walls extending between the top and bottom walls. The side walls extend to a bottom edge at the bottom wall and include mounting pins extending from the bottom edge that each have a press-fit portion configured to be press fit in a plated via of a circuit board. The bottom wall has a generally planar bottom surface facing the circuit board and a generally planar top surface facing the module cavity. The bottom wall includes a locating feature extending below the bottom surface and having a datum surface configured to engage the circuit board. The datum surface is a predetermined distance from the top surface to set a position of the top surface relative to the circuit board.
    Type: Grant
    Filed: January 16, 2017
    Date of Patent: November 26, 2019
    Assignee: TE CONNECTIVITY CORPORATION
    Inventors: Eric David Briant, Randall Robert Henry, Brandon Michael Matthews, James Charles Shiffler, Charles Jameson Valentine, Leo Joseph Graham
  • Publication number: 20190161477
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioblastoma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: May 30, 2019
    Inventors: Jolie Anne BASTIAN, Jiehao CHEN, Jeffrey Daniel COHEN, James Robert HENRY, William Thomas MCMILLEN, Bradley Earl REAMAN, Almudena RUBIO, Daniel Jon SALL, Gaiying ZHAO
  • Patent number: 10010540
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: January 17, 2017
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventor: James Robert Henry
  • Patent number: 9872853
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: January 23, 2018
    Assignee: Eli Lilly and Company
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • Publication number: 20170354641
    Abstract: The present invention relates to certain novel 2,3-dihydro-1H-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
    Type: Application
    Filed: May 31, 2017
    Publication date: December 14, 2017
    Inventors: Jolie Anne Bastian, Jiehao Chen, Jeffrey Daniel Cohen, James Robert Henry, William Thomas McMillen, Bradley Earl Reaman, Almudena Rubio, Daniel Jon Sall, Gaiying Zhao
  • Publication number: 20170119751
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Application
    Filed: January 17, 2017
    Publication date: May 4, 2017
    Inventor: James Robert Henry
  • Patent number: 9637474
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventor: James Robert Henry
  • Publication number: 20160137628
    Abstract: The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits Aurora A and, therefore may be useful in treating cancer.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 19, 2016
    Inventor: James Robert Henry
  • Patent number: 8114872
    Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: February 14, 2012
    Assignee: Eli Lilly and Company
    Inventors: Joyce Z. Crich, Delu Jiang, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Melissa Kate Slater, Yan Wang, James Robert Henry, Hong Hu, Sachin Govindlal Maniar
  • Patent number: 8101628
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Melissa Kate Slater, Yan Wang
  • Publication number: 20110294792
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 1, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Patent number: 8063035
    Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: November 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Joyce Z. Crich, James Robert Henry, Hong Hu, Delu Jiang, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Melissa Kate Slater, Yan Wang
  • Patent number: 8063212
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, morpholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: November 22, 2011
    Assignee: Eli Lilly and Company
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Jason Scott Sawyer, Yan Wang
  • Patent number: 8058425
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 15, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Patent number: 8022065
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 20, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Albert Engler, James Robert Henry, Sushant Malhotra, Jon Kevin Reel
  • Publication number: 20110207721
    Abstract: The present invention provides kinase inhibitors of Formula I.
    Type: Application
    Filed: May 4, 2011
    Publication date: August 25, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Thomas Albert Engler, Timothy Paul Burkholder, Joshua Ryan Clayton, Clive Gideon Diefenbacher, Kelly Wayne Furness, James Robert Henry, Yihong Li, Sushant Malhotra, Angela Lynn Marquart, Johnathan Alexander McLean, David Mendel, Jon Kevin Reel, Brian Raymond Berridge, Charles Edward Ruegg, John Morris Sullivan
  • Publication number: 20100130466
    Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
    Type: Application
    Filed: May 7, 2008
    Publication date: May 27, 2010
    Inventors: Harold Burns Brooks, Joyce Z. Crich, Delu Jiang, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Melissa Kate Slater, Yan Wang, James Robert Henry, Hong Hu, Sachin Govindlal Maniar
  • Publication number: 20100087431
    Abstract: The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.
    Type: Application
    Filed: May 7, 2008
    Publication date: April 8, 2010
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong Hu, Delu Jiang, Hong-Yu Li, William Thomas McMillen, Jason Scott Sawyer, Melissa Kate Slater, Yan Wang
  • Publication number: 20100081641
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N-ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino)-ethyl, 3,3,3-trifluoro-propylaminomethyl, ethynyl, 2-hydroxy-ethoxy, 2-hydroxyethylaminomethyl, 2-cyanoethylaminomethyl, mopholin-4-ylmethyl, methoxymethoxymethyl, cyclopropyl, 1-azetidinylmethyl, 1-pyrrolidinylmethyl, or 1,3-dioxolan-2-yl; R2 is hydrogen or halo; R3 is hydrogen or halo; provided that at least one of R2 and R3 is hydrogen; R4 is hydrogen, methyl, or halo; and is a single bond that is either present or absent, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2007
    Publication date: April 1, 2010
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Jason Scott Sawyer, Yan Wang
  • Publication number: 20100076001
    Abstract: The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or methylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo; R4 is hydrogen, halo, or methyl; provided that at least two of R1, R2, R3, and R4 are hydrogen; R5 is hydrogen, halo, or methyl; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2007
    Publication date: March 25, 2010
    Inventors: Harold Burns Brooks, Joyce Z. Crich, James Robert Henry, Hong-Yu Li, Melissa Kate Slater, Yan Wang